Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

被引：0
|
作者：
Klein, Austin T. [1 ,2 ,3 ]
Mendillo, Marc L. [1 ,2 ,3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA
[2] Northwestern Univ, Simpson Querrey Ctr Epigenet, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CELL CHEMICAL BIOLOGY | 2023年 / 30卷 / 11期
关键词：
D O I：
10.1016/j.chembiol.2023.10.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resis-tance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combi-nation therapeutic strategies.
引用
收藏
页码：1334 / 1336
页数：3
相关论文
共 50 条
  • [41] Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
    Muzumdar, Mandar Deepak
    Dorans, Kimberly Judith
    Chung, Katherine Minjee
    Robbins, Rebecca
    Tammela, Tuomas
    Gocheva, Vasilena
    Li, Carman Man-Chung
    Jacks, Tyler
    NATURE COMMUNICATIONS, 2016, 7
  • [42] The ERBB network facilitates KRas-driven lung tumorigenesis
    Kruspig, Bjorn
    Monteverde, Tiziana
    Neidler, Sarah
    Hock, Andreas
    Kerr, Emma
    Nixon, Colin
    Clark, William
    Hedley, Ann
    Dick, Craig
    Vousden, Karen
    Martins, Carla
    Murphy, Daniel
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (08) : 508 - 508
  • [43] Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
    Pan, Jing
    Zhang, Qi
    Sei, Shizuko
    Shoemaker, Robert H.
    Lubet, Ronald A.
    Wang, Yian
    You, Ming
    ONCOTARGET, 2017, 8 (47) : 82689 - 82699
  • [44] The ERBB network facilitates KRAS-driven lung tumorigenesis
    Kruspig, Bjorn
    Monteverde, Tiziana
    Neidler, Sarah
    Hock, Andreas
    Kerr, Emma
    Nixon, Colin
    Clark, William
    Hedley, Ann
    Laing, Sarah
    Coffelt, Seth B.
    Le Quesne, John
    Dick, Craig
    Vousden, Karen
    Martins, Carla P.
    Murphy, Daniel J.
    SCIENCE TRANSLATIONAL MEDICINE, 2018, 10 (446)
  • [45] KRAS-DRIVEN CANCERS ARE DEPENDENT ON METTL13-MEDIATED eEF1A METHYLATION
    不详
    CANCER DISCOVERY, 2019, 9 (02) : 163 - 163
  • [46] A one-two punch for KRAS-driven cancer
    Megan Cully
    Nature Reviews Drug Discovery, 2015, 14 : 600 - 600
  • [47] Role of downstream effectors in Kras-driven myeloproliferative disease
    Shieh, Angell C.
    Shannon, Kevin M.
    BLOOD, 2007, 110 (11) : 483A - 483A
  • [48] A requirement for FADD and its phosphorylation for KRAS-driven oncogenesis
    Bowman, Brittany M.
    Galban, Stefanie
    Hoff, Benjamin A.
    Heist, Kevin A.
    Boes, Jennifer L.
    Galban, Craig J.
    Patel, Rajiv M.
    Zhang, Jianke
    Ross, Brian D.
    Rehemtulla, Alnawaz
    CANCER RESEARCH, 2014, 74 (19)
  • [49] SENESCENT MACROPHAGES PROMOTE KRAS-DRIVEN LUNG TUMORIGENESIS
    Prieto, L., I
    Sturmlechner, I
    Graves, S., I
    Zhang, C.
    Goplen, N. P.
    Yi, E. S.
    Haston, S.
    Gonzalez-Gualda, E.
    Morsli, S.
    Ge, J.
    Reen, V
    Calderwood, A.
    CANCER DISCOVERY, 2023, 13 (08) : 1758 - 1758
  • [50] Activation of PKC inhibits oncogenic KRAS-driven malignancies
    Wang, Man-Tzu
    Galeas, Jacqueline
    McCormick, Frank
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12345